Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;190(4):e187-e189.
doi: 10.1111/bjh.16954. Epub 2020 Jul 9.

Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia

Julien Favresse  1   2 , Christine Eucher  1 , Marc Elsen  1 , Carlos Graux  3 , Paul Goebels  4 , Kim Laffineur  1 , Jean-Baptiste Nicolas  5 , Jean-Michel Dogné  2 , Jonathan Douxfils  2   6
Affiliations
Comment

Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia

Julien Favresse et al. Br J Haematol. 2020 Aug.
No abstract available

Keywords: COVID-19; SARS-CoV-2; kinetics; serology; symptom onset.

PubMed Disclaimer

Conflict of interest statement

Among the authors, Jonathan Douxfils is chief executive officer and founder of QUALIblood sa and reports personal fees from Diagnostica Stago, Roche, Roche Diagnostics, Daiichi‐Sankyo and Portola, outside the submitted work. Roche Diagnostics generously provided the kits for the validation.

Figures

Fig 1
Fig 1
(A) Seroconversion in 11 patients with serial samples (one colour per patient). Optimized cut‐off (i.e. >0·165) and the limit of quantification (LOQ) of the assay (i.e. >0·151) are represented with black‐ and grey‐dotted lines respectively. (B) Lymphocyte kinetics in 11 patients with serial samples (one colour per patient) from reverse transcription polymerase chain reaction (RT‐PCR) positivity. Reference interval is represented with black dotted lines.
See this image and copyright information in PMC

Comment on

References

    1. Baumann T, Delgado J, Montserrat E. CLL and COVID‐19 at the Hospital Clinic of Barcelona: an interim report. Leukemia. 2020. 10.1038/s41375-020-0870-5 - DOI - PMC - PubMed
    1. COVID‐19 and CLL: Frequently Asked Questions. https://www.hematology.org/covid‐19/covid‐19‐and‐cll Accessed June 4, 2020.
    1. Winter AK, Hegde ST. The important role of serology for COVID‐19 control. Lancet Infect Dis. 2020. 10.1016/S1473-3099(20)30322-4. - DOI - PMC - PubMed
    1. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS‐CoV‐2 in patients with COVID‐19. Nat Med. 2020;26(6):845–8. - PubMed
    1. Farnsworth CW, Anderson NW. SARS‐CoV‐2 serology: much hype, little data. Clin Chem. 2020. 10.1093/clinchem/hvaa107 - DOI - PMC - PubMed

Substances